109 related articles for article (PubMed ID: 12619930)
1. CytokineRegulation and the signaling mechanism of osteoclast inhibitory peptide-1 (OIP-1/hSca) to inhibit osteoclast formation.
Koide M; Maeda H; Roccisana JL; Kawanabe N; Reddy SV
J Bone Miner Res; 2003 Mar; 18(3):458-65. PubMed ID: 12619930
[TBL] [Abstract][Full Text] [Related]
2. Identification of the functional domain of osteoclast inhibitory peptide-1/hSca.
Koide M; Kurihara N; Maeda H; Reddy SV
J Bone Miner Res; 2002 Jan; 17(1):111-8. PubMed ID: 11771657
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.
Srinivasan S; Ito M; Kajiya H; Key LL; Johnson-Pais TL; Reddy SV
Gene; 2006 Apr; 371(1):16-24. PubMed ID: 16380218
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.
Shanmugarajan S; Youssef RF; Pati P; Ries WL; Rao DS; Reddy SV
J Cell Biochem; 2008 Jul; 104(4):1500-8. PubMed ID: 18348201
[TBL] [Abstract][Full Text] [Related]
5. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
6. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
7. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
8. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages.
Zhou R; Zheng SX; Tang W; He PL; Li XY; Yang YF; Li YC; Geng JG; Zuo JP
J Pharmacol Exp Ther; 2006 Jan; 316(1):121-8. PubMed ID: 16166270
[TBL] [Abstract][Full Text] [Related]
10. Eosinophil chemotactic factor-L (ECF-L): a novel osteoclast stimulating factor.
Oba Y; Chung HY; Choi SJ; Roodman GD
J Bone Miner Res; 2003 Jul; 18(7):1332-41. PubMed ID: 12854845
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts.
Nishida A; Andoh A; Shioya M; Kim-Mitsuyama S; Takayanagi A; Fujiyama Y
Am J Physiol Gastrointest Liver Physiol; 2008 Mar; 294(3):G831-8. PubMed ID: 18239058
[TBL] [Abstract][Full Text] [Related]
12. c-myc is required for osteoclast differentiation.
Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.
Aitken CJ; Hodge JM; Nishinaka Y; Vaughan T; Yodoi J; Day CJ; Morrison NA; Nicholson GC
J Bone Miner Res; 2004 Dec; 19(12):2057-64. PubMed ID: 15537450
[TBL] [Abstract][Full Text] [Related]
14. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
17. (5R)-5-hydroxytriptolide inhibits IFN-gamma-related signaling.
Zhou R; Wang JX; Tang W; He PL; Yang YF; Li YC; Li XY; Zuo JP
Acta Pharmacol Sin; 2006 Dec; 27(12):1616-21. PubMed ID: 17112417
[TBL] [Abstract][Full Text] [Related]
18. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
20. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
Merle B; Itzstein C; Delmas PD; Chenu C
J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
